D-BACE in Combination With Chemotherapy and Carelizumab for Resectable II-IIIA or Potentially Resectable T3-4N2 Stage IIIB NSCLC

NCT07016126 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

70

Enrollment

OTHER

Sponsor class

Conditions

NSCLC (Non-small Cell Lung Cancer)

Interventions

COMBINATION_PRODUCT: D-BACE in combination with chemotherapy and karelizumab

Sponsor

Guangdong Provincial People's Hospital